News & events Upcoming events Jun 29, 2022 - Jul 2, 2022 3rd Meeting of the Society for CSF Analysis and Clinical Neurochemistry Berlin, Germany More info and meet us there Jul 1, 2022 - Jul 2, 2022 36ª Reunião Anual do GEECD (Grupo de Estudo de Envelhecimento Cerebral e Demências) Coimbra, Portugal More info and meet us there Jul 3, 2022 - Jul 5, 2022 6th National Congress of the Italian Society of Virology (SIV-ISV) Naples, Italy More info and meet us there See all upcoming events Latest news Nov 19, 2021 Fujirebio Europe confirms engagement in new pathways for Alzheimer’s disease research and launches INNOTEST® assays for the two promising biomarkers NPTX2 and sTREM2 Fujirebio Europe today announced the commercial launch of two new cerebrospinal fluid (CSF) based immunoassays for the novel neurology... Read more Oct 28, 2021 Fujirebio Europe receives translational research funding from Alzheimer’s Drug Discovery Foundation for development of a fully automated plasma pTau181 testing solution H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio, today announced an agreement with the Diagnostics Accelerator... Read more Aug 18, 2021 Fujirebio Europe announces CE marking of the fully automated Lumipulse® G SARS-CoV-2 S-IgG assay Fujirebio Europe announces the CE marking of the Lumipulse G SARS-CoV-2 S-IgG assay, a quantitative antibody assay for a fully automated... Read more Jun 16, 2021 Fujirebio Europe launches iAMP® COVID-19 SANO Assay, a molecular detection assay that can be performed in saliva Gent, Belgium – June 16, 2021: Fujirebio Europe today announced the commercial launch of iAMP COVID-19 SANO (Saliva And Nasopharyngeal... Read more Jan 19, 2021 Statement on the impact of coronavirus disease Covid-19 on our operations The novel coronavirus disease Covid-19 first reported in late 2019 has spread worldwide. At Fujirebio Europe’s Belgian facilities, we are... Read more Dec 8, 2020 OHMX.bio and Fujirebio Europe receive grant of 720K EURO to incorporate third generation sequencing into clinical in vitro diagnostics platform Gent, Belgium, December 8, 2020 – OHMX.bio, a provider of cutting-edge “omics” solutions, and Fujirebio Europe announced today that they... Read more Load More
Jun 29, 2022 - Jul 2, 2022 3rd Meeting of the Society for CSF Analysis and Clinical Neurochemistry Berlin, Germany More info and meet us there
Jul 1, 2022 - Jul 2, 2022 36ª Reunião Anual do GEECD (Grupo de Estudo de Envelhecimento Cerebral e Demências) Coimbra, Portugal More info and meet us there
Jul 3, 2022 - Jul 5, 2022 6th National Congress of the Italian Society of Virology (SIV-ISV) Naples, Italy More info and meet us there
Nov 19, 2021 Fujirebio Europe confirms engagement in new pathways for Alzheimer’s disease research and launches INNOTEST® assays for the two promising biomarkers NPTX2 and sTREM2 Fujirebio Europe today announced the commercial launch of two new cerebrospinal fluid (CSF) based immunoassays for the novel neurology... Read more
Oct 28, 2021 Fujirebio Europe receives translational research funding from Alzheimer’s Drug Discovery Foundation for development of a fully automated plasma pTau181 testing solution H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio, today announced an agreement with the Diagnostics Accelerator... Read more
Aug 18, 2021 Fujirebio Europe announces CE marking of the fully automated Lumipulse® G SARS-CoV-2 S-IgG assay Fujirebio Europe announces the CE marking of the Lumipulse G SARS-CoV-2 S-IgG assay, a quantitative antibody assay for a fully automated... Read more
Jun 16, 2021 Fujirebio Europe launches iAMP® COVID-19 SANO Assay, a molecular detection assay that can be performed in saliva Gent, Belgium – June 16, 2021: Fujirebio Europe today announced the commercial launch of iAMP COVID-19 SANO (Saliva And Nasopharyngeal... Read more
Jan 19, 2021 Statement on the impact of coronavirus disease Covid-19 on our operations The novel coronavirus disease Covid-19 first reported in late 2019 has spread worldwide. At Fujirebio Europe’s Belgian facilities, we are... Read more
Dec 8, 2020 OHMX.bio and Fujirebio Europe receive grant of 720K EURO to incorporate third generation sequencing into clinical in vitro diagnostics platform Gent, Belgium, December 8, 2020 – OHMX.bio, a provider of cutting-edge “omics” solutions, and Fujirebio Europe announced today that they... Read more
